title: Validation of a diagnostic approach to exclude recurrent venous thromboembolism.
abstract: OBJECTIVE
  The diagnosis of recurrent venous thromboembolism (VTE) is a challenge in clinical practice. Our objective was to evaluate the safety of a diagnostic strategy utilizing comparison of diagnostic test results with baseline imaging results to rule out suspected recurrent VTE.
  
  
  METHODS
  The REVERSE study was a prospective cohort study whose primary aim was to develop a clinical prediction rule for recurrent VTE. We included and followed patients who completed 5-7 months of anticoagulant therapy after a first unprovoked VTE. Suspected cases of recurrent VTE were assessed according to standardized diagnostic criteria based on comparison of diagnostic test results with those obtained at the time of anticoagulant treatment withdrawal.
  
  
  RESULTS
  Out of the 398 suspected events, a recurrent VTE was diagnosed in 106 cases (26.6%) and excluded in 292 cases. In 76 cases (19%), the diagnosis of recurrent VTE was excluded on the basis of the fact that no significant change on diagnostic imaging was detected when compared to baseline imaging. During the ensuing 3 months, six patients received anticoagulant therapy after recurrent VTE was excluded, and two were lost to follow-up. Eight of 284 remaining patients in whom recurrent VTE had been excluded, who were not treated and who were not lost to follow-up were diagnosed with subsequent VTE (3-month risk, 2.8%; 95% confidence interval, 1.4-5.5%). Six of these eight patients with subsequent recurrent VTE had a known superficial or distal thrombosis at the time of initial suspected recurrent VTE.
  
  
  CONCLUSIONS
  A diagnostic strategy comparing diagnostic test results obtained at the time of the suspected recurrent event with those obtained at baseline can safely and effectively rule out recurrent VTE in a significant proportion of patients. Registered at http://www.clinicaltrials.gov identifier: NCT00261014.
authors.affiliation: Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
authors.forename: G
authors.initials: G
authors.lastname: Le Gal
authors.forename: M J
authors.initials: MJ
authors.lastname: Kovacs
authors.forename: M
authors.initials: M
authors.lastname: Carrier
authors.forename: K
authors.initials: K
authors.lastname: Do
authors.forename: S R
authors.initials: SR
authors.lastname: Kahn
authors.forename: P S
authors.initials: PS
authors.lastname: Wells
authors.forename: D A
authors.initials: DA
authors.lastname: Anderson
authors.forename: I
authors.initials: I
authors.lastname: Chagnon
authors.forename: S
authors.initials: S
authors.lastname: Solymoss
authors.forename: M
authors.initials: M
authors.lastname: Crowther
authors.forename: M
authors.initials: M
authors.lastname: Righini
authors.forename: A
authors.initials: A
authors.lastname: Perrier
authors.forename: R H
authors.initials: RH
authors.lastname: White
authors.forename: L
authors.initials: L
authors.lastname: Vickars
authors.forename: M
authors.initials: M
authors.lastname: Rodger
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage; D015331:Cohort Studies; D005500:Follow-Up Studies; D006801:Humans; D017063:Outcome Assessment, Health Care; D011237:Predictive Value of Tests; D012008:Recurrence; D054556:Venous Thromboembolism / Q000175:diagnosis* / Q000503:physiopathology / Q000517:prevention & control
chemical_list: D000925:Anticoagulants